1
Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With NALP3 Mutations and Clinical Symptoms
Condition(s):NALP3 MutationLast Updated:February 17, 2009Completed
NALP-3: 38 Clinical Trials, Page 1 of 4
Hide Studies Not Open or Pending
2
Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)
Condition(s):Cryopyrin-Associated Periodic SyndromeLast Updated:November 27, 2020Recruiting
3
The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada
Condition(s):Cryopyrin Associated Periodic SyndromeLast Updated:March 21, 2017Completed
4
A Clinical Study of Tranilast in the Treatment of Cryopyrin-Associated Periodic Syndrome (CAPS)
Condition(s):Cryopyrin-Associated Periodic SyndromesLast Updated:June 4, 2019Recruiting
5
Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
Condition(s):Cryopyrin-associated Periodic Syndromes; Familial Cold Autoinflammatory Syndrome; Muckle-Wells Syndrome; Neonatal Onset Multisystem Inflammatory DiseaseLast Updated:March 29, 2017Completed
6
Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase
Condition(s):Cryopyrin-associated Periodic Syndromes; Familial Cold Autoinflammatory Syndrome; Muckle-Wells Syndrome; Neonatal Onset Multisystem Inflammatory DiseaseLast Updated:September 25, 2020Completed
7
Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
Condition(s):Cryopyrin-Associated Periodic Syndromes; Familial Cold Autoinflammatory Syndrome; Muckle Wells Syndrome; Neonatal Onset Multisystem Inflammatory DiseaseLast Updated:November 4, 2016Completed
8
HL2351 CAPS Phase II Study
Condition(s):Cryopyrin-Associated Periodic Syndromes (CAPS)Last Updated:January 4, 2017Terminated
9
Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
Condition(s):Cryopyrin-associated Periodic Syndromes; Familial Cold Autoinflammatory Syndrome; Muckle-Wells Syndrome; Neonatal Onset Multisystem Inflammatory DiseaseLast Updated:September 11, 2018Completed
10
Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Condition(s):Familial Cold Autoinflammatory Syndrome (FCAS); Familial Cold Urticaria; Muckle-Wells Syndrome (MWS); Genetic Diseases, InbornLast Updated:December 6, 2011Completed